OTLC (Oncotelic Therapeutics) Shiller PE Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Oncotelic Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Oncotelic Therapeutics  (OTCPK:OTLC) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Oncotelic Therapeutics Shiller PE Ratio Related Terms


Oncotelic Therapeutics Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Oncotelic Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncotelic Therapeutics Shiller PE Ratio Chart

Oncotelic Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Oncotelic Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

OTLC vs DARE, PASG, INTS: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Oncotelic Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncotelic Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncotelic Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Oncotelic Therapeutics's Shiller PE Ratio falls into.



Oncotelic Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Oncotelic Therapeutics's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, Oncotelic Therapeutics's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.0008/333.9520*333.9520
=0.001

Current CPI (Jun. 2026) = 333.9520.

Oncotelic Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 -0.120 241.428 -0.166
201612 -0.130 241.432 -0.180
201703 -0.149 243.801 -0.204
201706 -0.150 244.955 -0.204
201709 -0.130 246.819 -0.176
201712 -0.090 246.524 -0.122
201803 -0.030 249.554 -0.040
201806 -0.025 251.989 -0.034
201809 -0.035 252.439 -0.047
201812 -0.024 251.233 -0.032
201903 -0.141 254.202 -0.185
201906 -0.018 256.143 -0.024
201909 -0.013 256.759 -0.017
201912 -0.041 256.974 -0.054
202003 -0.055 258.115 -0.071
202006 0.006 257.797 0.008
202009 -0.022 260.280 -0.029
202012 -0.038 260.474 -0.049
202103 -0.030 264.877 -0.038
202106 -0.009 271.696 -0.011
202109 -0.004 274.310 -0.005
202112 -0.005 278.802 -0.006
202203 -0.013 287.504 -0.015
202206 0.038 296.311 0.043
202209 -0.002 296.808 -0.002
202212 -0.014 296.797 -0.015
202303 -0.001 301.836 -0.001
202306 -0.017 305.109 -0.019
202309 0.000 307.789 0.000
202312 -0.002 306.746 -0.002
202403 -0.001 312.332 -0.001
202406 -0.001 314.175 -0.001
202409 -0.008 315.301 -0.009
202412 -0.002 315.605 -0.002
202503 -0.001 319.799 -0.001
202506 0.001 322.561 0.001
202509 -0.003 324.800 -0.003
202512 0.566 324.054 0.583
202603 -0.005 330.213 -0.005
202606 0.001 333.952 0.001

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Oncotelic Therapeutics Business Description

Address 29397 Agoura Road, Suite 107, Agoura Hills, CA, USA, 91301
Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer. OT-101 is its flagship immuno-oncology drug candidate. OT-101 also has activity against SARS-CoV-2. Its other products under the pipeline are Artemisinin, CA4P, AL-101, and Oxi4503.